Bienville Capital Management LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,779 shares of the company’s stock after selling 79 shares during the quarter. Bienville Capital Management LLC’s holdings in AbbVie were worth $854,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of the business. State Street Corp lifted its position in shares of AbbVie by 2.4% during the first quarter. State Street Corp now owns 72,969,530 shares of the company’s stock worth $4,754,696,000 after purchasing an additional 1,696,042 shares in the last quarter. Prudential Financial Inc. lifted its holdings in AbbVie by 41.5% in the second quarter. Prudential Financial Inc. now owns 5,469,241 shares of the company’s stock valued at $396,575,000 after buying an additional 1,603,748 shares during the period. Comerica Bank lifted its holdings in AbbVie by 81.7% in the second quarter. Comerica Bank now owns 1,849,149 shares of the company’s stock valued at $136,671,000 after buying an additional 831,625 shares during the period. Bank of Nova Scotia lifted its holdings in AbbVie by 297.9% in the first quarter. Bank of Nova Scotia now owns 606,321 shares of the company’s stock valued at $39,507,000 after buying an additional 453,955 shares during the period. Finally, Artemis Investment Management LLP lifted its holdings in AbbVie by 52.9% in the second quarter. Artemis Investment Management LLP now owns 1,055,834 shares of the company’s stock valued at $76,543,000 after buying an additional 365,259 shares during the period. 69.32% of the stock is currently owned by hedge funds and other institutional investors.
AbbVie Inc. (NYSE:ABBV) opened at $94.40 on Thursday. The firm has a market cap of $152,315.39, a price-to-earnings ratio of 17.97, a P/E/G ratio of 1.35 and a beta of 1.52. AbbVie Inc. has a 12-month low of $58.80 and a 12-month high of $98.52. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a yield of 3.01%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is currently 62.29%.
In other news, EVP Michael Severino sold 25,633 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the sale, the executive vice president now owns 114,922 shares in the company, valued at approximately $10,881,964.18. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now owns 93,099 shares of the company’s stock, valued at approximately $7,915,276.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 277,125 shares of company stock valued at $25,891,756. Corporate insiders own 0.23% of the company’s stock.
ABBV has been the topic of several analyst reports. Leerink Swann set a $106.00 target price on shares of AbbVie and gave the stock a “buy” rating in a report on Tuesday. BMO Capital Markets set a $84.00 target price on shares of AbbVie and gave the stock a “hold” rating in a report on Monday. ValuEngine lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Friday, December 1st. Societe Generale increased their target price on shares of AbbVie in a report on Tuesday, November 21st. Finally, BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 11th. Seven research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. AbbVie presently has an average rating of “Buy” and a consensus price target of $96.66.
ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/07/abbvie-inc-abbv-shares-sold-by-bienville-capital-management-llc.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
What are top analysts saying about AbbVie Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AbbVie Inc. and related companies.